Amycretin Side Effects: Safety Signals and Warnings
Amycretin safety concerns are compound-specific. The main listed side effects are Nausea (most common), Vomiting, and Diarrhea. The main warning signals are Investigational agent - not yet approved for clinical use, Long-term safety and efficacy data not yet available, and GI side effects may limit tolerability at higher doses.
Direct Answer
Amycretin, now called zenagamtide, is one of the most interesting next-generation obesity peptides because it combines GLP-1 and amylin agonism in a single molecule and has both oral and injectable programs. Phase 3 development is underway, but there is no Phase 3 outcome data yet, so it remains behind approved agents and behind retatrutide for near-term evidence.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Best for
- Weight loss research, oral GLP-1/amylin dual agonism pharmacology, obesity treatment development
Reported Side Effects
- Nausea (most common)
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
Warnings
- Investigational agent - not yet approved for clinical use
- Long-term safety and efficacy data not yet available
- GI side effects may limit tolerability at higher doses
- Potential pancreatitis risk (class effect of GLP-1 agonists)
- Thyroid C-cell tumor risk unknown (class concern for GLP-1 agonists in rodents)
Known or Plausible Interactions
- Oral medications (delayed gastric emptying may affect absorption)
- Insulin and sulfonylureas (additive hypoglycemia risk)
- Other GLP-1 receptor agonists (not intended for combination use)
Regulatory Context
Investigational new drug. Novo Nordisk has advanced zenagamtide/amycretin into Phase 3 development for weight management in 2026; it is not approved by any regulatory authority and is not available outside clinical trials.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Appetite Suppression (Level B), and Gastrointestinal Tolerability (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Amycretin Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-01. https://examinepeptides.com/answers/amycretin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.